Stock Comparison

ECOR vs PFE

electroCore, Inc. vs Pfizer Inc

The Verdict

PFE takes this one.

ECOR

electroCore, Inc.

2.5

out of 10

Risk Trap

Winner

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Head-to-Head

$79M

Market Cap

$146.4B

N/A

P/E Ratio

19.5

-44.1%

Profit Margin

11.8%

-235.8%

Return on Equity

8.4%

N/A

Debt-to-Equity

0.7

Aggressive

Overall Risk

Moderate

2.5

DVR Score

4.0

The Deep Dive

ECOR2.5/10

electroCore exhibits strong operational execution, evidenced by Q1 2026 revenue of $9.6M, representing a 42.64% YoY increase, and its gammaCore device addresses a vast market for headache disorders with patented, non-invasive technology. This market potential and product strength are compelling. However, these positives are severely undermined by critical financial distress. The company faces pers...

Full ECOR Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.